Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 1(7)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07447986Phase 2Recruiting

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Role: lead

NCT06167486Phase 1Active Not Recruiting

SG2918 For Advanced Malignant Tumors

Role: lead

NCT06144710Phase 1Active Not Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Role: lead

NCT07454187Phase 1Not Yet Recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06508983Phase 3Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Role: lead

NCT06076291Phase 1Active Not Recruiting

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

Role: lead

NCT05857332Phase 1Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors

Role: lead

NCT05293912Phase 1Terminated

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Role: lead

NCT04684108Phase 1Active Not Recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Role: lead

All 9 trials loaded